Zydus, a leading discovery based global pharmaceutical company announced that it has received approval from the regulatory authority of Mexico, COFEPRIS, for its one of its lead research candidate Desidustat to be tested in the management of COVID-19. Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Santé Research…
Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has initiated an accelerated research programme with multiple teams in India and Europe developing a vaccine for the novel coronavirus, 2019-nCo V (COVID-19) based on two approaches. The first approach deals with development of a DNA vaccine against the major viral membrane protein responsible for…
Zydus, a discovery based global pharmaceutical company, announced that it has entered into a licensing agreement with China Medical System Holdings Limited for the development and commercialization of Desidustat, a novel oral HlF-PH inhibitor for the treatment of anemia in patients with Chronic Kidney Disease (CKD) not—on—dialysis and for the treatment of Anemia CKD patients…